Page 136 - Read Online

3. McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia 27. Myking AO, Skeie GO,Varhaug JE, Andersen KS, Gilhus NE,
gravis: a systematic literature review. Neuroepidemiology Aarli JA. The histomorphology of the thymus in late onset,
2010;34:171‑83. non‑thymoma myasthenia gravis. Eur J Neurol 1998;5:401‑5.
4. Kawaguchi N, Kuwabara S, Nemoto Y, Fukutake T, Satomura Y, 28. Skeie GO, Romi F. Paraneoplastic myasthenia gravis: immunological
Arimura K, Osame M, Hattori T. Treatment and outcome of and clinical aspects. Eur J Neurol 2008;15:1029‑33.
myasthenia gravis: retrospective multi‑center analysis of 470 29. Evoli A, Minisci C, Di Schino C, Marsili F, Punzi C, Batocchi AP,
Japanese patients, 1999‑2000. J Neurol Sci 2004;224:43‑7. Tonali PA, Doglietto GB, Granone P, Trodella L, Cassano A,
5. Zhang X, Yang M, Xu J, Zhang M, Lang B, Wang W, Vincent A. Lauriola L. Thymoma in patients with MG: characteristics and
Clinical and serological study of myasthenia gravis in HuBei long‑term outcome. Neurology 2002;59:1844‑50.
Province, China. J Neurol Neurosurg Psychiatry 2007;78:386‑90. 30. Romi F, Aarli JA, Gilhus NE. Seronegative myasthenia gravis: disease
6. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic severity and prognosis. Eur J Neurol 2005;12:413‑8.
review of population based epidemiological studies in myasthenia 31. Wang SY, Xu XH, Sun H, Han X, Zhang H, Guo H. A clinical
gravis. BMC Neurol 2010;10:46. absolute and relative score system for myasthenia gravis. Chin J
7. Gattellari M, Goumas C, Worthington JM. A national Neurol 1997;30:87‑90.
epidemiological study of myasthenia gravis in Australia. Eur J 32. Chen P, Wang YP, Liu JJ, Dang GX. Application of clinical absolute
Neurol 2012;19:1413‑20. and relative score system in diagnosis for myasthenia gravis. J Fourth
8. Lai CH, Tseng HF. Nationwide population‑based epidemiological Mil Med Univ 2008;29:566‑8.
study of myasthenia gravis in Taiwan. Neuroepidemiology 33. Li ZY, Hu XQ, Neuroimmunology Branch of Chinese Society
2010;35:66‑71. for Immunology; Neuroimmunology Branch, Chinese Society of
9. Andersen JB, Engeland A, Owe JF, Gilhus NE. Myasthenia gravis Neurology, Chinese Medical Association. Consensus of Chinese
requiring pyridostigmine treatment in a national population cohort. experts in the diagnosis and treatment for myasthenia gravis. Chin
Eur J Neurol 2010;17:1445‑50. J Neuroimmunol Neurol 2012;19:401‑8.
10. MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The 34. Beekman R, Kuks JB, Oosterhuis HJ. Myasthenia gravis: diagnosis
incidence and lifetime prevalence of neurological disorders and follow‑up of 100 consecutive patients. J Neurol 1997;244:112‑8.
in a prospective community‑based study in the UK. Brain 35. Keesey JC. Clinical evaluation and management of myasthenia
2000;123:665‑76. gravis. Muscle Nerve 2004;29:484‑505.
11. Casetta I, Groppo E, De Gennaro R, Cesnik E, Piccolo L, Volpato S, 36. Kupersmith MJ, Latkany R, Homel P. Development of generalized
Granieri E. Myasthenia gravis: a changing pattern of incidence. disease at 2 years in patients with ocular myasthenia gravis. Arch
J Neurol 2010;257:2015‑9. Neurol 2003;60:243‑8.
12. Aragonès JM, Bolíbar I, Bonfill X, Bufill E, Mummany A, Alonso F, 37. Schlezinger NS, Fairfax WA. Evaluation of ocular signs and
Illa I. Myasthenia gravis: a higher than expected incidence in the symptoms in myasthenia gravis. Arch Ophthalmol 1959;62:985‑90.
elderly. Neurology 2003;60:1024‑6. 38. Leeamornsiri S, Chirapapaisan N, Chuenkongkaew W. Clinical
13. Liu WB , Men LN, He XT, Xia Q, Huang RX. Clinical analysis on profiles of Thai patients with ocular myasthenia gravis in Siriraj
1520 patients with myasthenia gravis in southern China. Chin J Hospital. J Med Assoc Thai 2011;94:1117‑21.
Neuroimmunol Neurol 2006;13:326‑30. 39. Jing J, Zhang XJ, Yu L, Chen RL, Qin NN, Ma S. Factors affecting
14. Xu JZ, Yang MS, Li BH, Jiang HP, Zhang RX, Xu SB. Myasthenia the progression from ocular to generalized myasthenia gravis. Chin
gravis: clinical study in 2385 patients. Chin J Neurol 1999;32:347‑50. J Neurol 2014;47:21‑5.
15. Wang W, Chen YP, Wang ZK, Wei DN, Yin L. A cohort study on 40. Yang ZX, Xiong H, Zhang YH, Bao XH, Jiang YW, Wu Y, Wang S,
myasthenia gravis patients in China. Neurol Sci 2013;34:1759‑64. Chang XZ, Qin J, Lin Q, Wu XR. Clinical characteristics and
16. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of follow‑up management of 135 children with myasthenia gravis.
myasthenia gravis. Muscle Nerve 2008;37:141‑9. Beijing Da Xue Xue Bao 2011;43:455‑9.
17. Osserman KE, Genkins G. Studies in myasthenia gravis: review of 41. Hong YH, Kwon SB, Kim BJ, Kim BJ, Kim SH, Kim JK, Park KS,
a twenty‑year experience in over 1200 patients. Mt Sinai J Med Park KJ, Sung JJ, Sohn EH, Lee YB, Jeong D, Joo IS, Choi BO,
1971;38:497‑537. Choi YC, Korean Research Group for Neuromuscular D. Prognosis
18. Thanvi BR, Lo TC. Update on myasthenia gravis. Postgrad Med J of ocular myasthenia in Korea: a retrospective multicenter analysis
2004;80:690‑700. of 202 patients. J Neurol Sci 2008;273:10‑4.
19. Phillips LH 2nd. The epidemiology of myasthenia gravis. Ann N Y 42. Kupersmith MJ. Ocular myasthenia gravis: treatment successes
Acad Sci 2003;998:407‑12. and failures in patients with long‑term follow‑up. J Neurol
20. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, 2009;256:1314‑20.
Penn AS, Sanders DB. Myasthenia gravis: recommendations for 43. Guan YZ, Cui LY, Liu MS, Wang H, Zhang JB, Li YF. Progression
clinical research standards. Task Force of the Medical Scientific from ocular to generalized myasthenia gravis in adults. Chin J Neurol
Advisory Board of the Myasthenia Gravis Foundation of America. 2012;45:866‑8.
Neurology 2000;55:16‑23. 44. Allen JA, Scala S, Jones HR. Ocular myasthenia gravis in a senior
21. Compston DA, Vincent A, Newsom‑Davis J, Batchelor JR. Clinical, population: diagnosis, therapy, and prognosis. Muscle Nerve
pathological, HLA antigen and immunological evidence for disease 2010;41:379‑84.
heterogeneity in myasthenia gravis. Brain 1980;103:579‑601. 45. Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V,
22. Kuks JB, Limburg PC, Horst G, Oosterhuis HJ. Antibodies to skeletal Dichgans J. Ocular myasthenia gravis: response to long‑term
muscle in myasthenia gravis. Part 2. Prevalence in non‑thymoma immunosuppressive treatment. J Neurol Neurosurg Psychiatry
patients. J Neurol Sci 1993;120:78‑81. 1997;62:156‑62.
23. Romi F, Skeie GO, Aarli JA, Gilhus NE. Muscle autoantibodies in 46. Weinberg DH, Rizzo JF 3rd, Hayes MT, Kneeland MD, Kelly JJ Jr.
subgroups of myasthenia gravis patients. J Neurol 2000;247:369‑75. Ocular myasthenia gravis: predictive value of single‑fiber
24. Agius MA, Richman DP, Fairclough RH, Aarli J, Gilhus NE, electromyography. Muscle Nerve 1999;22:1222‑7.
Romi F. Three forms of immune myasthenia. Ann N Y Acad Sci
2003;998:453‑6.
25. Gilhus NE, Owe JF, Hoff JM, Romi F, Skeie GO, Aarli JA. Myasthenia Cite this article as: Guo J, Dang D, Li HZ, Li ZY. Current overview of
myasthenia gravis and experience in China. Neuroimmunol Neuroinflammation
gravis: a review of available treatment approaches. Autoimmune 2014;1(3):127-30.
Dis 2011;2011:847393.
26. Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Source of Support: Nil. Conflict of Interest: No.
Myasthenia gravis: a review. Autoimmune Dis 2012;2012:874680. Received: 05-08-2014; Accepted: 16-09-2014

130 Neuroimmunol Neuroinflammation | Volume 1 | Issue 3 | December 2014